PDPs: A New Relationship to Change the World

We've all heard the term globalization before and understand this term as our world growing smaller and more reliant on one another as a result. This interconnectedness of globalization, has led to an explosion in the global health field and the number of organizations devoted to solving the world's problems has multiplied significantly. From this movement in global health has come the necessity of partnerships. Partnerships in the global health world has come to be essential in pooling resources, knowledge, and improving population coverage offering the best services available. Public-private partnerships (PPPs) and product development partnerships (PDPs) are a few examples of the type of partnerships to be aware of. Without globalization, these different organizations and groups would cease to exist and would cease to have realized the need for one another to increase impact and save lives.

As PDPs are a big part of my research at the moment at Research! America, I wanted to take a moment to delve into the importance of these and shed light on the success stories of PDPs that receive far to little media attention.

What are PDPs?

These are partnerships across public, private and foundation entities working together to speed up the R&D pipeline to bring products faster to market. The keyword here is products, which means this unique partnership has a more concrete goal than PPPs. Often biotechs and pharmaceutical companies are involved and play a critical role in the clinical trials portion. Since PDPs began they have centered around neglected tropical disease products (ie: visceral leishmaniasis, dengue, trachoma, schistosomiasis, and diarrheal diseases). Today, PDPs around vaccine research has grown as vaccines for TB, HIV/AIDs, malaria, dengue, rotavirus, and meningitis are advancing in significant ways.

What are the successes we need to be aware of?

• GAVI (5million future deaths have been prevented, because the increased immunisations GAVI has funded and distributed, Nov 2010)





• PATH-MenAfriVac (20 million have been vaccinated in the meningitis belt in Africa. The meningitis vaccine was made specifically for this region and expectations have been beyond met.) Click here for more.





• One World Health's antibiotic paromomycin intramuscular injection (PMIM) treatment for visceral leishmaniasis ("black fever"/"kala-azar"). Results in Phase 4/India have shown major success and this treatment is inexpensive.

more to be added to this list......

I am constantly amazed how perplexed my colleagues are about product development partnerships. To me they make sense if we look at the progression of time and understand the timeline of global health, they benefit and are cost-effective for all players involved, and have the potential to save more lives than ever before. To me PDPs are not meant to be underestimated and should be carefully observed. These relationships between global entities have the potential to change the world as we know it today, into the future we want it to become.

Vaccines; A Best Buy in Global Health

Everyone deserves a shot at life. Studies show that vaccines reduce childhood morbidity and mortality while simultaneously being cost-effective. Many vaccines for children only cost a few cents including measles (23 cents), polio (13 cents) and meningitis (50 cents). Vaccines save lives and are a great return on investment. For every one year increase in average life expectancy, countries achieve an average 4% increase in GDP per capita (Bloom et al, 2004). It is well worth the research efforts to improve life quality and reduce childhood mortality. While we know that health research is a long-term process, our investments in life-saving vaccines and other global health research have yielded effective partnerships and major success stories.

Today, many innovative partnerships are working together to pool expertise and address the research and accessibility challenges associated with vaccine and many global health efforts. One of today’s greatest success stories is a private-public partnership (PPP), the Global Alliance for Vaccines and Immunizations Initiative (GAVI). Using innovative financing mechanisms to bolster support for vaccines in the developing world, GAVI distributed routine immunizations like measles, tetanus, polio, hepatitis B, and pertussis in over 70 countries. To date, GAVI’s efforts have prevented the deaths of 5 million children (WHO-UNICEF coverage estimates for 1980-2009, as of July 2010).

We need to continue to support organizations like GAVI that embody research and innovation at its finest. As the GAVI pledging conference is around the corner (June 13th, London), we
need to remember that vaccines are the tool we need to save lives and the best buy in global health we have available to us to bring hope and a future to the world’s children and communities. The time to provide others with a shot at life is now.